Skip to content Skip to footer

WG2

Sigma-1 receptor in neurodegenerative, inflammatory, cancer and cardiometabolic diseases

Sigma-1 receptor is a multi-faceted protein that is involved in numerous physiopathological pathways. The main aim of this WG is to identify the mechanistic links between the pathogenesis of neurodegenerative, inflammatory, cancer and cardiometabolic diseases and the modulation of sigma-1 receptor activity by ligands. With the aid of the molecules/probes developed in WG1, the Action particularly address the exact molecular mechanisms and their contribution to complex neuroprotective and neurorestorative processes; develop approaches for the treatment of neuropathic or inflammatory pain; and aim at a clear understanding of sigma-1 receptor function in tumour cell growth and/or apoptosis.

Tasks and Activities

Task 2.1
Identification of molecular mechanisms and signalling pathways connected with sigma-1 receptor in the different pathologies, from neurological and neurodegenerative diseases to pain, cancer and cardiometabolic diseases
Task 2.2
Identification of sigma-1 receptor role in cytoprotection and maintenance and restoration of brain function in different CNS pathologies
Task 2.3
Attainment of new analgesics targeting sigma-1 receptor for pain treatment
Task 2.4
Identification of the mechanisms involved in anti-tumour activities of sigma-1 receptor ligands
Task 2.5
Analysis of the potential of sigma-1 receptor activation/inhibition in combination therapies
task 2.6
Evaluation of the possibility to target sigma-1 receptor as a prognostic/diagnostic marker in diseases

Deliverables

D2.1
Finding out sigma-1 receptor molecular mechanisms and signalling pathways (articles, communications)
D2.2
Identification of sigma-1 receptor as diagnostic/prognosis marker (articles)
D2.3
Identification of the mechanisms involved in the pharmacological activities of S1R ligands in different indications (agonists/antagonists) (compounds)
D2.4
To analyze the potential of sigma-1 receptor activation/inhibition in combination therapies (articles)

What is COST?

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

COST ACTION CA23156

The SIGMA-1 EUROPE Action is dedicated to promoting excellence in research and innovation related to sigma-1 receptor physiopathology and therapeutic applications across multiple fields. This initiative fosters interdisciplinary collaboration to drive breakthrough science and technological advancements in medicinal chemistry and pharmaceutical development.

Action Details

Action Start Date: October 25, 2024
Action End Date: October 24, 2028

© 2025. All rights reserved. – Privacy PolicyPrivacy settings

Created by elaboranext